Soligenix, Inc. (SNGX) has a number of important catalysts ahead in the second half of 2025. The company is currently conducting the Phase 3 FLASH2 trial of HyBryte (SGX301) for the treatment of early-stage cutaneous T cell lymphoma (CTCL). We anticipate an update on enrollment in the 2H25, with topline results expected in the 2H26. A clinical update is expected in the 3Q25 for the ongoing investigator-initiated study (IIS) sponsored by Dr. Ellen Kim, which is evaluating extended HyBryte treatment for up to 54 weeks. Topline results are expected in the Phase 2a trial of SGX302 in mild-to-moderate psoriasis. Lastly, topline results are expected in the Phase 2a proof-of-concept trial of Behcet's Disease with SGX945 in the 3Q25.
